Rigel Pharmaceuticals RIGL

NAS: RIGL | ISIN: US7665596034   5/12/2025
48,92 USD (+3,25%)
(+3,25%)   5/12/2025

26 november 2025 · Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference · Persbericht

17 november 2025 · Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology · Persbericht

12 november 2025 · Rigel to Present at the Jefferies Global Healthcare Conference in London · Persbericht

4 november 2025 · Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update · Persbericht

3 november 2025 · Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition · Persbericht

29 oktober 2025 · Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update · Persbericht

8 oktober 2025 · Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS · Persbericht

3 oktober 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

26 augustus 2025 · Rigel to Participate in Upcoming September Investor Conferences · Persbericht

5 augustus 2025 · Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update · Persbericht

29 juli 2025 · Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update · Persbericht

7 juli 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

28 mei 2025 · Rigel to Present at the Jefferies Global Healthcare Conference · Persbericht

22 mei 2025 · Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress · Persbericht

6 mei 2025 · Rigel Reports First Quarter 2025 Financial Results and Provides Business Update · Persbericht

29 april 2025 · Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update · Persbericht

4 april 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

27 maart 2025 · Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation · Persbericht

10 maart 2025 · Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors · Persbericht

4 maart 2025 · Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update · Persbericht

Mijn selecties